688443 Share Price Performance
CN¥27.02
2.22 (8.95%)
Price CN¥27.02
Share Pricen/a
Chongqing Genrix Biopharmaceutical Co., Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
688443 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Chongqing Genrix Biopharmaceutical Co., Ltd. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 30, 2026
- -1.46
- 100.00%
- -232.41%
- 58.6%
About 688443
- Founded
- 2015
- Employees
- 793
- CEO
- WebsiteView website
Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a monoclonal antibody for VZV infection; GR1803, a bispecific antibody for multiple myeloma; GR1901, a bispecific antibody; WM202 a bispecific antibody; WM215, a single-domain antibody; GR1401, an anti-EGFR monoclonal antibody; and GR1405 an anti-PD-L1 monoclonal antibody. The company was founded in 2015 and is based in Chongqing, China.
